Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

Novartis has exclusive rights to MRT-6160 and follow-up VAV1 degraders and will be responsible for development activities from phase 2 onwards, after Boston-based Monte Rosa completes its phase 1 ...